Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

UNITED THERAPEUTICS CORPORATION

(UTHR)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
259.68 USD   -1.72%
01/26Insider Sell: United Therapeutics
MT
01/24Insider Sell: United Therapeutics
MT
01/20Insider Sell: United Therapeutics
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
258.84(c) 260.42(c) 265.92(c) 264.23(c) 259.68(c) Last
269 612 196 443 360 747 246 713 217 997 Volume
-1.09% +0.61% +2.11% -0.64% -1.72% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 966 M - -
Net income 2022 821 M - -
Net cash position 2022 692 M - -
P/E ratio 2022 15,3x
Yield 2022 -
Sales 2023 2 221 M - -
Net income 2023 946 M - -
Net cash position 2023 1 601 M - -
P/E ratio 2023 13,5x
Yield 2023 -
Capitalization 11 835 M 11 835 M -
EV / Sales 2022 5,67x
EV / Sales 2023 4,61x
Nbr of Employees 965
Free-Float 62,0%
More Financials
Company
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil)... 
More about the company
Ratings of United Therapeutics Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about UNITED THERAPEUTICS CORPORATION
01/26Insider Sell: United Therapeutics
MT
01/24Insider Sell: United Therapeutics
MT
01/20Insider Sell: United Therapeutics
MT
01/19Insider Sell: United Therapeutics
MT
01/18Insider Sell: United Therapeutics
MT
01/13Insider Sell: United Therapeutics
MT
01/11Insider Sell: United Therapeutics
MT
01/11Argus Adjusts Price Target on United Therapeutics to $300 From $250, Maintains Buy Rati..
MT
01/09Insider Sell: United Therapeutics
MT
01/09Transcript : United Therapeutics Corporation Presents at 41st Annual J.P. Mor..
CI
01/09United Therapeutics Corp : Regulation FD Disclosure (form 8-K)
AQ
01/05Insider Sell: United Therapeutics
MT
01/03Insider Sell: United Therapeutics
MT
01/02United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Co..
BU
2022Insider Sell: United Therapeutics
MT
More news
News in other languages on UNITED THERAPEUTICS CORPORATION
01/26Vente d'initiés : United Therapeutics
01/24Vente d'initiés : United Therapeutics
01/20Vente d'initiés : United Therapeutics
01/19Vente d'initiés : United Therapeutics
01/18Vente d'initiés : United Therapeutics
More news
Analyst Recommendations on UNITED THERAPEUTICS CORPORATION
More recommendations
ETFs positioned on UNITED THERAPEUTICS CORPORATIONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
First Trust NYSE Arca Biotechnology - Acc - USD4.67%2.10%-United_States
The Acquirers Fund ETF - USD3.35%3.12%-NC
Invesco Dynamic Pharmaceuticals ETF - USD3.23%-0.37%United_States
Invesco DWA Healthcare Momentum ETF - USD2.96%-1.17%United_States
First Trust AlphaDEX U.S. Health Care Secto...2.87%0.66%-United_States
More ETFs positioned on UNITED THERAPEUTICS CORPORATION
Chart UNITED THERAPEUTICS CORPORATION
Duration : Period :
United Therapeutics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNITED THERAPEUTICS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 259,68 $
Average target price 279,92 $
Spread / Average Target 7,80%
EPS Revisions
Managers and Directors
Martine A. Rothblatt Chairman & Chief Executive Officer
Michael Ian Benkowitz President & Chief Operating Officer
James Christopher Edgemond Chief Financial Officer & Treasurer
Raymond C. Kurzweil Independent Director
Louis Wade Sullivan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
UNITED THERAPEUTICS CORPORATION-6.62%11 835
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.64%28 465
SEAGEN INC.9.46%26 117